ATXS · As filed with the SEC
Astria Therapeutics cash flow statement, by fiscal year
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | Year ended Dec 31, 2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net loss | (94,260,000) | (72,891,000) | (51,834,000) | (194,912,000) | (37,300,000) | (26,293,000) | (25,870,000) | (27,364,000) |
| Reconciliation of net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | — | — | — | — | — | 26,000 | 119,000 | 304,000 |
| Non-cash portion of acquired in-process research and development | — | — | — | 164,612,000 | — | — | — | — |
| Stock-based compensation expense | 13,042,000 | 6,314,000 | 4,554,000 | 3,362,000 | 1,390,000 | 1,512,000 | 1,771,000 | 2,007,000 |
| Accretion of discount/premium on investment securities | — | — | — | — | — | 5,000 | (6,000) | 26,000 |
| Non-cash interest expense | — | — | — | — | — | — | 37,000 | 155,000 |
| Gain on disposal of property and equipment | — | — | — | — | — | 18,000 | (297,000) | (30,000) |
| Services received in non-monetary exchange | — | — | — | — | — | 33,000 | 19,000 | — |
| Net gain on warrants inherited in acquisition of Quellis | — | — | 1,542,000 | 71,000 | — | — | — | — |
| Right-of-use asset- operating lease | 1,004,000 | 585,000 | (554,000) | — | — | — | — | — |
| Accretion of discount/premium on investment securities | (5,611,000) | — | — | — | — | — | — | — |
| Other non-cash items | 70,000 | (40,000) | 112,000 | 21,000 | 58,000 | — | — | — |
| Changes in assets and liabilities: | ||||||||
| Prepaid expenses and other assets | (1,252,000) | (4,546,000) | (1,568,000) | 85,000 | 1,257,000 | (1,289,000) | (177,000) | (93,000) |
| Other assets | — | — | — | — | — | — | (85,000) | — |
| Right-of-use asset-operating | — | — | — | — | — | (96,000) | — | — |
| Lease liability - operating lease | (731,000) | (610,000) | 574,000 | (109,000) | 176,000 | — | — | — |
| Accounts payable | 2,807,000 | 725,000 | (766,000) | (1,965,000) | 347,000 | (211,000) | 662,000 | (632,000) |
| Accrued expenses | 3,719,000 | 2,018,000 | 4,407,000 | (1,316,000) | 1,587,000 | (205,000) | 396,000 | (1,215,000) |
| Deferred rent | — | — | — | — | — | — | (81,000) | 6,000 |
| Other liabilities | — | — | — | — | — | (69,000) | 47,000 | — |
| Net cash used in operating activities | (81,212,000) | (68,445,000) | (43,533,000) | (30,151,000) | (32,485,000) | (26,569,000) | (23,465,000) | (26,836,000) |
| Investing activities | ||||||||
| Sales and maturities of available-for-sale securities | — | — | — | — | — | — | — | 14,910,000 |
| Purchases of short-term investments | (4,244,538,000) | (1,924,423,000) | (396,064,000) | (78,000,000) | (62,777,000) | (155,197,000) | (70,364,000) | — |
| Sales and maturities of short-term investments | 4,053,000,000 | 2,059,500,000 | 229,026,000 | 59,000,000 | 69,110,000 | 151,127,000 | 48,090,000 | — |
| Cash acquired in acquisition of Quellis | — | — | — | 6,466,000 | — | — | — | — |
| Purchases of property and equipment | (325,000) | (25,000) | (91,000) | (21,000) | (33,000) | (12,000) | — | (57,000) |
| Proceeds from sale of property and equipment | — | — | — | — | — | — | 369,000 | 30,000 |
| Net cash (used in) provided by investing activities | (191,863,000) | 135,052,000 | (167,129,000) | (12,555,000) | 6,300,000 | (4,082,000) | (21,905,000) | 14,883,000 |
| Financing activities | ||||||||
| Proceeds from public offering, net of underwriting discounts and issuance costs | 117,172,000 | 59,480,000 | 107,646,000 | — | 24,559,000 | 18,505,000 | 38,886,000 | — |
| Proceeds from at-the-market offering, net of issuance costs | — | — | — | — | — | 7,061,000 | 8,253,000 | 8,036,000 |
| Proceeds from exercise of common stock options and warrants | — | — | — | — | — | 54,000 | — | — |
| Payments on borrowing | — | — | — | — | — | — | (2,848,000) | (3,333,000) |
| Proceeds from private offering of public equity, net of issuance costs | — | — | — | 104,261,000 | — | — | — | — |
| Proceeds from at-the-market offering, net of issuance costs | 35,245,000 | 28,498,000 | 36,991,000 | — | 16,270,000 | — | — | — |
| Proceeds from exercise of stock options | — | — | 84,000 | 23,000 | 31,000 | — | 4,000 | 23,000 |
| Proceeds from exercise of stock options and warrants | 4,785,000 | 420,000 | — | — | — | — | — | — |
| Net cash provided by financing activities | 157,202,000 | 88,398,000 | 144,721,000 | 104,284,000 | 40,860,000 | 25,620,000 | 44,295,000 | 4,726,000 |
| Net (decrease) increase in cash and cash equivalents | — | — | — | — | — | — | — | (7,227,000) |
| Cash and cash equivalents, beginning of period | — | — | — | — | — | — | 16,369,000 | 23,596,000 |
| Cash and cash equivalents, end of period | — | — | — | — | — | — | — | 16,369,000 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (115,873,000) | 155,005,000 | (65,941,000) | 61,578,000 | 14,675,000 | (5,031,000) | (1,075,000) | — |
| Cash, cash equivalents and restricted cash, beginning of period | 175,693,000 | 20,688,000 | 86,629,000 | 25,051,000 | 10,376,000 | 15,407,000 | 16,482,000 | — |
| Cash, cash equivalents and restricted cash, end of period | 59,820,000 | 175,693,000 | 20,688,000 | 86,629,000 | 25,051,000 | 10,376,000 | 15,407,000 | — |
| Supplemental disclosure of non-cash transactions: | ||||||||
| Cash paid for interest | — | — | — | — | — | — | 79,000 | 327,000 |
| Fixed asset purchases included in accounts payable | — | — | — | — | — | — | 18,000 | — |
| At-the-market issuance costs included in current liabilities | — | — | — | — | — | 65,000 | 110,000 | — |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 5,753,000 | — | 1,268,000 | — | — | — | — | — |
| Conversion of Series X Preferred Stock into common stock | — | 1,074,000 | — | 168,920,000 | — | — | — | — |
| Non-cash dividend on convertible preferred stock | — | — | — | 24,437,000 | — | — | — | — |
| Reclassification of warrant liability to additional paid-in capital | — | — | — | 3,468,000 | — | — | — | — |
| Purchases of property and equipment in accounts payable and accrued liabilities | — | 17,000 | — | — | — | — | — | — |
| Public offering issuance costs in accrued expenses | — | 120,000 | — | — | — | — | — | — |
| Public offering issuance costs in accrued expenses | — | — | 100,000 | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.